Bausch + Lomb Introduces New Surgical Planning Software for Eyetelligence™ Platform
VAUGHAN, Ontario, Oct. 24, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today introduced new surgical planning software for the Eyetelligence platform. The new software is designed to streamline surgical planning, information flow and enable electronic medical record (EMR) and diagnostic device integration.
In 2018, Bausch + Lomb launched Eyetelligence to help surgeons work smarter and more efficiently using cloud-based technology. Building upon that vision, this new software allows surgeons to simplify the complex and time-consuming surgical planning process,” said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb. “This is the first of many software releases planned as we continue to refine and expand upon the platform’s capabilities to meet the ever-evolving needs of doctors, clinics and their patients.”
The new Eyetelligence surgical planning software delivers a seamless, secure flow of information from the office to the operating room, ensuring surgeons can manage data and personalize their approach to each case digitally without the need for multiple documents, sources and folders. This connection across all aspects of the procedure is aimed to help avoid lost data and time. Surgeons will also be able to work with various EMR and diagnostic platforms, eliminating the need to purchase specific equipment or train staff on new technologies.
The Eyetelligence surgical planning software will offer both a surgeon-focused app and a nursing-focused app. These apps provide access to critical, timely data related to the patient and procedure, while enhancing communication and helping to improve workflow.
The Eyetelligence platform also includes software to connect to Bausch + Lomb’s Stellaris Elite® Vision Enhancement System, storing critical data to aid in surgical procedure analytics. The platform also allows surgeons to access settings on all their Stellaris Elite machines and provides fast access to remote technical support.
“As a high-volume cataract surgeon, I am all too familiar with the challenges of managing data from multiple sources,” said Mark Lobanoff, M.D., director, refractive surgery, OVO LASIK + LENS, Minneapolis, and founder of Lochan, LLC, the company that Bausch + Lomb entered an agreement with in 2021 to further develop the software. “Eyetelligence surgical planning software addresses these challenges, making the surgeon’s life easier.”
###
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
© 2023 Bausch + Lomb.
ETG.0021.USA.23
Media Contact:
Kristy Marks
[email protected]
(908) 927-0683
Investor Contact:
George Gadkowski
[email protected]
(877) 354-3705 (toll free)
(908) 927-0735